NASDAQ:EGRX - Eagle Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$41.90 +1.37 (+3.38 %)
(As of 02/15/2019 04:00 PM ET)
Previous Close$41.90
Today's Range$40.66 - $42.14
52-Week Range$36.03 - $85.66
Volume159,159 shs
Average Volume180,128 shs
Market Capitalization$624.85 million
P/E Ratio12.43
Dividend YieldN/A
Beta1.69
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL). Its product candidates includes include EP-3101, (bendamustine ready-to-dilute) for CLL and indolent B-cell NHL; EP-4104, a dantrolene sodium for exertional heat stroke; EGL-4104-C-1702, dantrolene sodium for drug induced hyperthermia; EP-5101 (pemetrexed) for lung cancer and mesothelioma; and EGL-5385-C-1701 (fulvestrant) for breast cancer. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Receive EGRX News and Ratings via Email

Sign-up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EGRX
CUSIPN/A
Phone201-326-5300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$236.71 million
Cash Flow$4.0918 per share
Book Value$12.01 per share

Profitability

Net Income$51.94 million

Miscellaneous

Employees108
Market Cap$624.85 million
OptionableOptionable

Eagle Pharmaceuticals (NASDAQ:EGRX) Frequently Asked Questions

What is Eagle Pharmaceuticals' stock symbol?

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

How will Eagle Pharmaceuticals' stock buyback program work?

Eagle Pharmaceuticals declared that its Board of Directors has initiated a share buyback program on Thursday, August 10th 2017, which authorizes the company to repurchase $100,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 13.3% of its stock through open market purchases. Stock repurchase programs are often a sign that the company's leadership believes its stock is undervalued.

How were Eagle Pharmaceuticals' earnings last quarter?

Eagle Pharmaceuticals Inc (NASDAQ:EGRX) released its quarterly earnings results on Tuesday, August, 7th. The specialty pharmaceutical company reported $0.95 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.80 by $0.15. The specialty pharmaceutical company earned $59.30 million during the quarter, compared to analysts' expectations of $51.78 million. Eagle Pharmaceuticals had a return on equity of 17.62% and a net margin of 13.92%. View Eagle Pharmaceuticals' Earnings History.

When is Eagle Pharmaceuticals' next earnings date?

Eagle Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, February 25th 2019. View Earnings Estimates for Eagle Pharmaceuticals.

What price target have analysts set for EGRX?

4 equities research analysts have issued 1-year price targets for Eagle Pharmaceuticals' stock. Their predictions range from $52.00 to $80.00. On average, they expect Eagle Pharmaceuticals' stock price to reach $62.50 in the next twelve months. This suggests a possible upside of 49.2% from the stock's current price. View Analyst Price Targets for Eagle Pharmaceuticals.

What is the consensus analysts' recommendation for Eagle Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eagle Pharmaceuticals in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Eagle Pharmaceuticals.

What are Wall Street analysts saying about Eagle Pharmaceuticals stock?

Here are some recent quotes from research analysts about Eagle Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey. " (2/14/2019)
  • 2. Cantor Fitzgerald analysts commented, "Eagle has carved out a leading position in the specialty pharma market, via its 505(b) (2) strategy. We expect upwards earnings revisions to the Street’s current forecasts as the company advances its pipeline and provides date-certain launch timeframes for its pipeline. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $80." (10/3/2018)

Has Eagle Pharmaceuticals been receiving favorable news coverage?

News coverage about EGRX stock has trended neutral on Saturday, InfoTrie reports. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Eagle Pharmaceuticals earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned news coverage about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next several days.

Who are some of Eagle Pharmaceuticals' key competitors?

Who are Eagle Pharmaceuticals' key executives?

Eagle Pharmaceuticals' management team includes the folowing people:
  • Mr. Scott L. Tarriff, CEO & Director (Age 58)
  • Mr. David M. Pernock, Pres & Chief Operating Officer (Age 65)
  • Mr. Pete A. Meyers, Chief Financial Officer (Age 48)
  • Dr. Adrian Hepner, Exec. VP & Chief Medical Officer (Age 57)
  • Mr. Daniel O'Connor, Exec. VP of Biologics and Corp. Devel. (Age 38)

Who are Eagle Pharmaceuticals' major shareholders?

Eagle Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (11.61%), Park West Asset Management LLC (7.04%), JW Asset Management LLC (2.85%), D. E. Shaw & Co. Inc. (1.91%), Millennium Management LLC (1.91%) and WINTON GROUP Ltd (1.59%). Company insiders that own Eagle Pharmaceuticals stock include David Pernock, Douglas L Braunstein, Pete A Meyers, Proquest Investments Iv, LP, Richard A Edlin, Sander A Flaum, Scott Tarriff and Steven L Krill. View Institutional Ownership Trends for Eagle Pharmaceuticals.

Which major investors are selling Eagle Pharmaceuticals stock?

EGRX stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Rothschild & Co. Asset Management US Inc., New York State Common Retirement Fund, JW Asset Management LLC, Bank of New York Mellon Corp, Northern Trust Corp, Canada Pension Plan Investment Board and Amundi Pioneer Asset Management Inc.. Company insiders that have sold Eagle Pharmaceuticals company stock in the last year include Sander A Flaum and Scott Tarriff. View Insider Buying and Selling for Eagle Pharmaceuticals.

Which major investors are buying Eagle Pharmaceuticals stock?

EGRX stock was purchased by a variety of institutional investors in the last quarter, including Park West Asset Management LLC, Millennium Management LLC, WINTON GROUP Ltd, D. E. Shaw & Co. Inc., Two Sigma Investments LP, Citigroup Inc., Chartwell Investment Partners LLC and Dimensional Fund Advisors LP. Company insiders that have bought Eagle Pharmaceuticals stock in the last two years include David Pernock, Douglas L Braunstein, Pete A Meyers and Richard A Edlin. View Insider Buying and Selling for Eagle Pharmaceuticals.

How do I buy shares of Eagle Pharmaceuticals?

Shares of EGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eagle Pharmaceuticals' stock price today?

One share of EGRX stock can currently be purchased for approximately $41.90.

How big of a company is Eagle Pharmaceuticals?

Eagle Pharmaceuticals has a market capitalization of $624.85 million and generates $236.71 million in revenue each year. The specialty pharmaceutical company earns $51.94 million in net income (profit) each year or $3.37 on an earnings per share basis. Eagle Pharmaceuticals employs 108 workers across the globe.

What is Eagle Pharmaceuticals' official website?

The official website for Eagle Pharmaceuticals is http://www.eagleus.com.

How can I contact Eagle Pharmaceuticals?

Eagle Pharmaceuticals' mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The specialty pharmaceutical company can be reached via phone at 201-326-5300 or via email at [email protected]


MarketBeat Community Rating for Eagle Pharmaceuticals (NASDAQ EGRX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  351 (Vote Outperform)
Underperform Votes:  213 (Vote Underperform)
Total Votes:  564
MarketBeat's community ratings are surveys of what our community members think about Eagle Pharmaceuticals and other stocks. Vote "Outperform" if you believe EGRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EGRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2019 by MarketBeat.com Staff

Featured Article: Correction

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel